iPRECIO®, Innovative Drug Infusion Technology for Laboratory Animals

Innovative drug infusion technology for laboratory animals.

News

Benson et al. (2026) addressed a potential circadian confound – the time of day when infusion pumps were implanted – by using programmable iPRECIO pumps to standardize drug delivery timing across subjects, illustrating a proactive approach to experimental design

Benson, Lance N., et al. "Time of Day Drives Angiotensin II–Dependent Hypertension."
Hypertension 83.2 (2026): e25906.
https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25906
https://pmc.ncbi.nlm.nih.gov/articles/PMC12826273/
January 26, 2026
Slide deck from Dr. Jamie Oliver, Chief Medical Officer of Starton Therapeutics available on Labroots. Results from 3 different studies with iPRECIO pumps were shared in the webinar.

Latest peer-reviewed publications from our users highlight how iPRECIO programmable pumps enable complex dosing regimens and consistent exposure profiles in free-moving subjects.
January 23, 2026
Webinar | Tuesday, October 29, 2025

Development of a Low-dose Percutaneous Delivery System for Lenalidomide in Hematologic Malignancies: From Ideation to Phase 2
Discover how Starton Therapeutics advanced their innovation journey—leveraging iPRECIO^® Programmable Pumps in proof-of-concept in-vivo studies—to transform early research into clinical success.

>> Register and details
August 22, 2025
Congratulations Arialys Therapeutics on your new peer-reviewed data published in Nature Communications demonstrating the potential of your lead candidate, ART5803, to address anti-NMDA receptor encephalitis and related autoimmune neuropsychiatric diseases. First time for us to see our SMP-200 pumps used for disease induction and disease treatment in a peer reviewed publication.

Kanno, A., Kito, T., Maeda, M. et al. Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis. Nat Commun 16, 5292 (2025). https://doi.org/10.1038/s41467-025-60628-1
June 20, 2025
Latest references updated. For our latest iPRECIO Applications Examples and Tabular highlights, contact us by e-mail to iprecio@primetech.co.jp or through our contact form. https://www.iprecio.com/contact/form/tabid/482/Default.aspx
April 3, 2025

Go to News Archives

Our Mission with
iPRECIO^® Product Portfolio:

Make it as easy as possible to evaluate efficacy of molecules/agents in different animal models and species.

Make the results as relevant as possible to the clinic. (Exposure profile, quantitative pharmacology, untethered free moving (stress free, group housing (socialization), ..…)

The use of iPRECIO^® pumps will have a positive impact on experimental conditions and the relevance of results achieved. Initial costs maybe higher but in the long run the use of the pump could be cost saving in the context of the whole compound development.

Page top